Mean platelet volume seems to be a valuable marker in patients with systemic sclerosis

Inflammation

Volumn 37, Issue 1, 2014, Pages 100-106

  Soydinc, Serdar ^a   Turkbeyler, Ibrahim Halil ^b   Pehlivan, Yavuz ^c   Soylu, Gulcimen ^d   Goktepe, Mehmet Fatih ^d   Bilici, Muhammed ^d   Zengin, Orhan ^d   Kisacik, Bunyamin ^d   Onat, Ahmet Mesut ^d  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ADIYAMAN UNIVERSITY   (Turkey)

^c ULUDAG UNIVERSITY   (Turkey)

^d GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

diseases activity; mean platelet volume; systemic sclerosis

Indexed keywords

ILOPROST;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DISEASE ACTIVITY; DISEASE MARKER; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINGER MALFORMATION; FINGER ULCER; GANGRENE; GASTROINTESTINAL DISEASE; HEMATOLOGICAL PARAMETERS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INFLAMMATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME;

DUDLEYA EDULIS; MOROCCAN PEPPER VIRUS;

BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; GASTROINTESTINAL DISEASES; HEART DISEASES; HUMANS; LUNG DISEASES; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN ULCER;

EID: 84900362961     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9716-x     Document Type: Article

References (38)

1. LeRoy, E.C. 1996. Systemic sclerosis. A vascular perspective. Rheumatic Diseases Clinics of North America 22: 675-694. (Pubitemid 26396045)
2. Kahaleh, M.B., and E.C. Leroy. 1999. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31: 195-214. (Pubitemid 30179202)
3. Kahaleh, M.B. 2004. Vascular involvement in systemic sclerosis (SSc). Clinical and Experimental Rheumatology 22: 19-23.
4. Gear, A.R., and D. Camerini. 2003. Platelet chemokines and chemokine receptors: Linking hemostasis, inflammation, and host defense. Microcirculation 10: 335-350. (Pubitemid 39004260)
5. Weyrich, A.S., S. Lindemann, and G.A. Zimmerman. 2003. The evolving role of platelets in inflammation. Journal of Thrombosis and Haemostasis 1: 1897-1905.
6. Martin, J.F., T. Shaw, J. Heggie, and D.G. Penington. 1983. Measurement of the density of human platelets and its relationship to volume. British Journal of Haematology 54: 337-352. (Pubitemid 13054556)
7. Martin, J.F., P.M.W. Bath, and M.L. Burr. 1991. Influence of platelet size on outcome after myocardial infarction. Lancet 338: 1409-1411.
8. Berger, J.S., L.H. Eraso, D. Xie, D. Sha, and E.R. Mohler 3rd. 2010. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis 213(2): 586-591.
9. Pattanaik, D., M. Brown, and A.E. Postlethwaite. 2011. Vascular involvement in systemic sclerosis (scleroderma). Journal of Inflammation Research 4: 105-125.
10. Friedhoff, L.T., J.R. Seibold, H.C. Kim, and K.S. Simester. 1984. Serotonin induced platelet aggregation in systemic sclerosis. Clinical and Experimental Rheumatology 2: 119-123. (Pubitemid 14055557)
11. Postlethwaite, A.E., and T.M. Chiang. 2007. Platelet contributions to the pathogenesis of systemic sclerosis. Current Opinion in Rheumatology 19: 574-579. (Pubitemid 47530878)
12. Masi, A.T., T.A. Medsger, G.P. Rodnan, et al. 1980. Preliminary criteria for the classification of systemic sclerosis. Arthritis and Rheumatism 23: 581-590. (Pubitemid 10101764)
13. Clements, P., P. Lachenbruch, J. Seibold, et al. 1995. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. Journal of Rheumatology 22: 1281-1285.
14. Valentini, G., A. Della Rossa, S. Bombardieri, et al. 2001. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Annals of the Rheumatic Diseases 60: 592-598. (Pubitemid 32493986)
15. Medsger Jr., T.A., A.J. Silman, V.D. Steen, et al. 1999. A disease severity scale for systemic sclerosis: Development and testing. Journal of Rheumatology 26: 2159-2167. (Pubitemid 29487010)
16. Gawaz, M. 2004. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovascular Research 61: 498-511. (Pubitemid 38210155)
17. Anitua, E., I. Andia, B. Ardanza, P. Nurden, and A.T. Nurden. 2004. Autologous platelets as a source of proteins for healing and tissue regeneration. Thrombosis and Haemostasis 91: 4-15. (Pubitemid 38111215)
18. Villeneuve, J., A. Block, M.C. Le Bousse-Kerdiles, S. Lepreux, P. Nurden, J. Ripoche, et al. 2009. Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: A novel organization for these secreted proteins. Experimental Hematology 37: 849-856.
19. Yanaba, K., K. Takehara, and S. Sato. 2004. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: Association with lower frequency of pulmonary fibrosis. Annals of the Rheumatic Diseases 63: 583-587. (Pubitemid 38530205)
20. Frenette, P.S., C.V. Denis, L. Weiss, K. Jurk, S. Subbarao, B. Kehrel, et al. 2000. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. Journal of Experimental Medicine 191: 1413-1422. (Pubitemid 30227127)
21. Kasper, B., and F. Petersen. 2011. Molecular pathways of platelet factor 4/CXCL4 signaling. European Journal of Cell Biology 90: 521-526.
22. Maeda, M., H. Kachi, and S. Mori. 1998. Ultrastructural observation of platelets from patients with progressive systemic sclerosis (PSS). Journal of Dermatology 25: 222-230. (Pubitemid 28216915)
23. Allanore, Y., D. Borderie, C. Meune, H. Lemarechal, S. Weber, O.G. Ekindjian, et al. 2005. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Annals of the Rheumatic Diseases 64: 481-483. (Pubitemid 40283065)
24. Komura, K., S. Sato, M. Hasegawa, M. Fujimoto, and K. Takehara. 2004. Elevated circulating CD40L concentrations in patients with systemic sclerosis. Journal of Rheumatology 31: 514-519. (Pubitemid 38337611)
25. Herrick, A.L., K. Illingworth, A. Blann, C.R. Hay, S. Hollis, and M.I. Jayson. 1996. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Annals of the Rheumatic Diseases 55: 122-127. (Pubitemid 26050121)
26. Guiducci, S., J.H. Distler, A. Jungel, D. Huscher, L.C. Huber, B.A. Michel, et al. 2008. The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis and Rheumatism 58: 2845-2853.
27. Fonseca, C., D. Abraham, and M. Ponticos. 2009. Neuronal regulators and vascular dysfunction in Raynaud's phenomenon and systemic sclerosis. Current Vascular Pharmacology 7: 34-39.
28. Silveri, F., R. De Angelis, A. Poggi, S. Muti, G. Bonapace, F. Argentati, et al. 2001. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scandinavian Journal of Rheumatology 30: 290-296. (Pubitemid 32980342)
29. Polidoro, L., R. Barnabei, P. Giorgini, L. Petrazzi, C. Ferri, and G. Properzi. 2012. Platelet activation in patients with the Raynaud's Phenomenon. Internal Medicine Journal 42: 531-535.
30. Zaldivar, M.M., K. Pauels, P. von Hundelshausen, M.L. Berres, P. Schmitz, J. Bornemann, et al. 2010. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 51: 1345-1353.
31. Dees, C., A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, A. Horn, et al. 2011. Platelet-derived serotonin links vascular disease and tissue fibrosis. Journal of Experimental Medicine 208: 961-972.
32. Abou-Raya, A., S. Abou-Raya, and M. Helmii. 2008. Statins: Potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. Journal of Rheumatology 35: 1801-1808.
33. Matucci-Cerinic, M., and J.R. Seibold. 2008. Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford, England) 47: 46-47.
34. Hak, A.E., E.W. Karlson, D. Feskanich, M.J. Stampfer, and K.H. Costenbader. 2009. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. Arthritis and Rheumatism 61: 1396-1402.
35. Balbaloglu O, Korkmaz M, Yolcu S, Karaaslan F, Beceren NG. 2013. Evaluation of mean platelet volume (MPV) levels in patients with synovitis associated with knee osteoarthritis. Platelets. doi:10.3109/09537104.2013.776162
36. Kisacik, B., A. Tufan, U. Kalyoncu, O. Karadag, A. Akdogan, M.A. Ozturk, S. Kiraz, I. Ertenli, and M. Calguneri. 2008. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint, Bone, Spine 75: 291-294.
37. Gasparyan, A.Y., A. Sandoo, A. Stavropoulos-Kalinoglou, and G.D. Kitas. 2010. Mean platelet volume in patients with rheumatoid arthritis: The effect of anti-TNF-α therapy. Rheumatology International 30: 1125-1129.
38. Stürzebecher, C.S. 1987. Effects of iloprost on platelet activation in vitro. In Prostacyclin and its stable analogue iloprost, ed. R.J. Gryglewski and G. Stock, 39-45. Berlin: Springer.